Literature DB >> 18349132

Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells.

Kennichi Satoh1, Shin Hamada, Kenji Kimura, Atsushi Kanno, Morihisa Hirota, Jun Umino, Wataru Fujibuchi, Atsushi Masamune, Naoki Tanaka, Koh Miura, Shinichi Egawa, Fuyuhiko Motoi, Michiaki Unno, Barbara K Vonderhaar, Tooru Shimosegawa.   

Abstract

MSX2 is thought to be a regulator of organ development and a downstream target of the ras signaling pathway; however, little is known about the role of MSX2 in the development of pancreatic cancers, most of which harbor a K-ras gene mutation. Therefore, we examined whether the presence of MSX2 correlates with the malignant behavior of pancreatic cancer cells. BxPC3 pancreatic cancer cells that stably overexpress MSX2 showed a flattened and scattered morphology accompanied by a change in localization of E-cadherin and beta-catenin from membrane to cytoplasm. Cell proliferation rate, cell migration, and anchorage-independent cell growth were enhanced in MSX2-expressing cells. Injection of MSX2-expressing cells into the pancreas of nude mice resulted in a significant increase in liver metastases and peritoneal disseminations compared with injection of control cells. Microarray analysis revealed a significant induction of Twist 1 expression in cells that express MSX2. When MSX2 was inactivated in pancreatic cancer cells following transfection with an MSX2-specific small interfering RNA, Twist 1 was down-regulated. Immunohistochemistry of human pancreatic carcinoma tissue revealed that MSX2 was frequently expressed in cancer cells, and that increased expression of MSX2 significantly correlated with higher tumor grade, vascular invasion, and Twist 1 expression. These data indicate that MSX2 plays a crucial role in pancreatic cancer development by inducing changes consistent with epithelial to mesenchymal transition through enhanced expression of Twist 1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349132      PMCID: PMC2276419          DOI: 10.2353/ajpath.2008.070346

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Ectopic Msx2 overexpression inhibits and Msx2 antisense stimulates calvarial osteoblast differentiation.

Authors:  M Dodig; T Tadic; M S Kronenberg; S Dacic; Y H Liu; R Maxson; D W Rowe; A C Lichtler
Journal:  Dev Biol       Date:  1999-05-15       Impact factor: 3.582

2.  The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.

Authors:  E Batlle; E Sancho; C Francí; D Domínguez; M Monfar; J Baulida; A García De Herreros
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

3.  Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.

Authors:  Anthony D Yang; E Ramsay Camp; Fan Fan; Lanlan Shen; Michael J Gray; Wenbiao Liu; Ray Somcio; Todd W Bauer; Yan Wu; Daniel J Hicklin; Lee M Ellis
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

4.  Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer.

Authors:  Yelena Mironchik; Paul T Winnard; Farhad Vesuna; Yoshinori Kato; Flonne Wildes; Arvind P Pathak; Scott Kominsky; Dmitri Artemov; Zaver Bhujwalla; Paul Van Diest; Horst Burger; Carlotta Glackin; Venu Raman
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

5.  Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.

Authors:  Haiyan Liu; Wei Liu; Yinwei Wu; Yue Zhou; Rong Xue; Chan Luo; Lan Wang; Wei Zhao; Jian-Dong Jiang; Jingwen Liu
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

6.  PDX-1 and Msx-2 expression in the regenerating and developing pancreas.

Authors:  M R Kritzik; E Jones; Z Chen; M Krakowski; T Krahl; A Good; C Wright; H Fox; N Sarvetnick
Journal:  J Endocrinol       Date:  1999-12       Impact factor: 4.286

7.  Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.

Authors:  Jian-Su Shao; Su-Li Cheng; Joyce M Pingsterhaus; Nichole Charlton-Kachigian; Arleen P Loewy; Dwight A Towler
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

8.  Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line.

Authors:  Shin Hamada; Kennichi Satoh; Morihisa Hirota; Kenji Kimura; Atsushi Kanno; Atsushi Masamune; Tooru Shimosegawa
Journal:  J Cell Physiol       Date:  2007-12       Impact factor: 6.384

9.  Msx2 gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: a possible mechanism for MSX2-mediated craniosynostosis in humans.

Authors:  Y H Liu; Z Tang; R K Kundu; L Wu; W Luo; D Zhu; F Sangiorgi; M L Snead; R E Maxson
Journal:  Dev Biol       Date:  1999-01-15       Impact factor: 3.582

10.  Progesterone enhances branching morphogenesis in the mouse mammary gland by increased expression of Msx2.

Authors:  K Satoh; R C Hovey; T Malewski; A Warri; A S Goldhar; E Ginsburg; K Saito; J P Lydon; B K Vonderhaar
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

View more
  36 in total

1.  Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.

Authors:  Kyoung Eun Lee; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

2.  MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.

Authors:  Y Zhai; A Iura; S Yeasmin; A B Wiese; R Wu; Y Feng; E R Fearon; K R Cho
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

3.  Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.

Authors:  Dong-Yuan Zhu; Qi-Sen Guo; Yan-Liang Li; Bin Cui; Jun Guo; Ji-Xiao Liu; Peng Li
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

4.  Inducible knockout of Twist1 in young and adult mice prolongs hair growth cycle and has mild effects on general health, supporting Twist1 as a preferential cancer target.

Authors:  Yan Xu; Yixiang Xu; Lan Liao; Niya Zhou; Sarah M Theissen; Xin-Hua Liao; Hoang Nguyen; Thomas Ludwig; Li Qin; Jarrod D Martinez; Jun Jiang; Jianming Xu
Journal:  Am J Pathol       Date:  2013-07-30       Impact factor: 4.307

5.  B-cell receptor-associated protein 31 promotes migration and invasion in ovarian cancer cells.

Authors:  Haiyan Liang; Jiqiao Dong; Ziyan Cheng; Qian Li; Dingqing Feng; Bin Ling
Journal:  Exp Ther Med       Date:  2021-06-09       Impact factor: 2.447

6.  Twist1 regulates the epithelial-mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma.

Authors:  Nannan Lv; Zhongyan Shan; Yun Gao; Haixia Guan; Chenling Fan; Hong Wang; Weiping Teng
Journal:  Endocrine       Date:  2015-08-20       Impact factor: 3.633

7.  MSX2 inhibits the growth and migration of osteosarcoma cells by repressing SOX2.

Authors:  Yue Wu; Yi Jin; Norio Yamamoto; Akihiko Takeuchi; Shinji Miwa; Hiroyuki Tsuchiya; Zhijun Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 8.  Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.

Authors:  Douglas S Micalizzi; Susan M Farabaugh; Heide L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-19       Impact factor: 2.673

9.  Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro.

Authors:  Fiona Lanigan; Gabriela Gremel; Rowena Hughes; Donal J Brennan; Finian Martin; Karin Jirström; William M Gallagher
Journal:  Breast Cancer Res       Date:  2010-08-03       Impact factor: 6.466

Review 10.  Twist: a molecular target in cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Han-chun Chen; Dianzheng Zhang; Junjiang Fu
Journal:  Tumour Biol       Date:  2013-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.